GSK Acquires a Preclinical Trispecific Myeloma TCE
GSK agreed to acquire full global rights to a preclinical trispecific T-cell engager from Chimagen Biosciences for multiple myeloma. Chimagen is eligible for an undisclosed upfront payment and development and commercial milestones bringing total…
